A historical analysis of oncology deals can help bioentrepreneurs navigate the right time for partnerships and exits and can inform on the type of investors likely to be interested.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
05 November 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-01142-9
References
Prencipe, D. The European venture capital landscape: an EIF perspective. Volume III: Liquidity events and returns of EIF-backed VC investments. https://www.fi-compass.eu/sites/default/files/publications/eif_wp_41.pdf(European Investment Fund, 2017).
Booth, B. New data on venture capital returns: exits are indeed improving. Forbes https://www.forbes.com/sites/brucebooth/2012/10/03/new-data-on-venture-capital-returns-exits-are-indeed-improving/?sh=36f724379d69 (2012).
Thomas, D. et al. Clinical development success rates and contributing factors 2011–2020. https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020 (BIO | QLS Advisors | Informa UK, 2021).
Paul, S. M. et al. Nat. Rev. Drug Discov. 9, 203–214 (2010).
Micklus, A. & Giglio, P. Nat. Rev. Drug Discov. 19, 87–88 (2020).
Giniatullina, A., Boorsma, M., Mulder, G. J. & van Deventer, S. Nat. Biotechnol. 31, 284–287 (2013).
Melchner von Dydiowa, G., van Deventer, S. & Couto, D. S. Nat. Biotechnol. 39, 266–269 (2021).
Hardison, S. Biopharma Dealmakers 15, 83–85 (2021).
Albrecht, B., Capra, E., Reichert, M. & Salazar, P. Precision medicine in practice: strategies for rare cancers. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/precision-medicine-in-practice-strategies-for-rare-cancers (McKinsey, 2021).
Fidler, B. Record numbers of biotechs are going public. Here’s how they’re performing. BioPharma Dive https://www.biopharmadive.com/news/biotech-ipo-performance-tracker/587604/ (2021).
Cameron, T. & Morrison, C. Nat. Rev. Drug Discov. 20, 93–94 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors are employed by Aglaia Oncology Funds, which invests in oncology start-ups.
Rights and permissions
About this article
Cite this article
de Bloeme, C.M., Jansen, R.W., Krul, M.R.L. et al. Stepping to the exit. Nat Biotechnol 39, 1048–1054 (2021). https://doi.org/10.1038/s41587-021-01007-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01007-1
This article is cited by
-
Navigating the right deals in oncology
Biopharma Dealmakers (2023)